| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2245 | 2019 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 531 | 2019 |
| Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial RW Beck, TD Riddlesworth, K Ruedy, A Ahmann, S Haller, D Kruger, ... Annals of internal medicine 167 (6), 365-374, 2017 | 511 | 2017 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 491 | 2019 |
| Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis R Aronson, HJ Offman, RT Joffe, CD Naylor Archives of general psychiatry 53 (9), 842-848, 1996 | 490 | 1996 |
| Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L) MC Riddle, R Aronson, P Home, M Marre, E Niemoeller, P Miossec, ... Diabetes care 36 (9), 2489-2496, 2013 | 357 | 2013 |
| Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo … MC Riddle, T Forst, R Aronson, L Sauque-Reyna, E Souhami, L Silvestre, ... Diabetes care 36 (9), 2497-2503, 2013 | 313 | 2013 |
| Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case … FM Sacks, MP Hermans, P Fioretto, P Valensi, T Davis, E Horton, ... Circulation 129 (9), 999-1008, 2014 | 303 | 2014 |
| Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes … J Rosenstock, R Aronson, G Grunberger, M Hanefeld, PM Piatti, ... Diabetes Care 39 (11), 2026-2035, 2016 | 293 | 2016 |
| Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin‐treated type 1 and type 2 diabetes: the global HAT study K Khunti, S Alsifri, R Aronson, M Cigrovski Berković, C Enters‐Weijnen, ... Diabetes, obesity and metabolism 18 (9), 907-915, 2016 | 283 | 2016 |
| Serum urate lowering with allopurinol and kidney function in type 1 diabetes A Doria, AT Galecki, C Spino, R Pop-Busui, DZ Cherney, I Lingvay, ... New England Journal of Medicine 382 (26), 2493-2503, 2020 | 270 | 2020 |
| Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial Y Reznik, O Cohen, R Aronson, I Conget, S Runzis, J Castaneda, SW Lee The Lancet 384 (9950), 1265-1272, 2014 | 257 | 2014 |
| A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately … SG Swinnen, MP Dain, R Aronson, M Davies, HC Gerstein, AF Pfeiffer, ... Diabetes care 33 (6), 1176-1178, 2010 | 203 | 2010 |
| Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M) B Ahrén, A Leguizamo Dimas, P Miossec, S Saubadu, R Aronson Diabetes care 36 (9), 2543-2550, 2013 | 201 | 2013 |
| Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal‐P) M Pinget, R Goldenberg, E Niemoeller, I Muehlen‐Bartmer, H Guo, ... Diabetes, Obesity and Metabolism 15 (11), 1000-1007, 2013 | 166 | 2013 |
| Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 … J Rosenstock, B Guerci, M Hanefeld, S Gentile, R Aronson, FJ Tinahones, ... Diabetes care 39 (8), 1318-1328, 2016 | 147 | 2016 |
| Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes R Aronson, PA Gottlieb, JS Christiansen, TW Donner, E Bosi, BW Bode, ... Diabetes care 37 (10), 2746-2754, 2014 | 145 | 2014 |
| The role of comfort and discomfort in insulin therapy R Aronson Diabetes technology & therapeutics 14 (8), 741-747, 2012 | 116 | 2012 |
| Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial EA Bohula, BM Scirica, SE Inzucchi, DK McGuire, AC Keech, SR Smith, ... The Lancet 392 (10161), 2269-2279, 2018 | 85 | 2018 |
| Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study R Aronson, J Frias, A Goldman, A Darekar, B Lauring, SG Terra Diabetes, Obesity and Metabolism 20 (6), 1453-1460, 2018 | 84 | 2018 |
